Biological Variability of Serum and Urinary N-Telopeptides of Type I Collagen in Postmenopausal Women
Open Access
- 1 March 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 15 (3) , 594-598
- https://doi.org/10.1359/jbmr.2000.15.3.594
Abstract
Measurement of N‐telopeptides of type I bone collagen (NTX) provides a specific indicator of the current level of bone resorption. The biological intrasubject variability of NTX in urine and serum was studied in 277 postmenopausal women, mean age, 63.6 years ± 10.2 (±SD) years. Second‐morning void urine and serum specimens were collected at baseline and for two consecutive days to determine short‐term variability (%CV). Long‐term variability was determined by comparing NTX results at baseline and two consecutive months. Subjects were instructed to maintain current diet, lifestyle, and medications during the study. The median short‐term %CV was 13.1% for urine NTX. This compared with 6.3% for serum NTX. Calculation of long‐term %CV showed similar trends, with the %CV for NTX measured in serum (7.5%) lower than when measured in urine (15.6%). Using the least significant change (LSC) calculation, our data show that to be 90% confident that a decrease in NTX after initiation of antiresorptive therapy in an individual patient is not caused by variability alone, a 31% decrease in urine NTX and a 14% decrease in serum NTX is required. As reported changes in NTX caused by antiresorptive therapy are greater than these calculations; our results support the use of either specimen to measure NTX to monitor the effect of therapy.Keywords
This publication has 16 references indexed in Scilit:
- Novel Serum Markers of Bone Resorption: Clinical Assessment and Comparison with Established Urinary IndicesJournal of Bone and Mineral Research, 1999
- Monitoring Alendronate Therapy for OsteoporosisJournal of Bone and Mineral Research, 1999
- Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical TrialJournal of Bone and Mineral Research, 1998
- Response of Biochemical Markers of Bone Turnover to Hormone Replacement Therapy: Impact of Biological VariabilityJournal of Bone and Mineral Research, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Hormone Replacement Therapy in Postmenopausal Women: Urinary N-Telopeptide of Type I Collagen Monitors Therapeutic Effect and Predicts Response of Bone Mineral DensityThe American Journal of Medicine, 1997
- Molecular Site Specificity of Pyridinoline and Pyrrole Cross-links in Type I Collagen of Human BoneJournal of Biological Chemistry, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorptionJournal of Bone and Mineral Research, 1994
- A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urineJournal of Bone and Mineral Research, 1992